SG Americas Securities LLC Lowers Stock Holdings in Exelixis, Inc. $EXEL

SG Americas Securities LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 87.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,617 shares of the biotechnology company’s stock after selling 498,036 shares during the period. SG Americas Securities LLC’s holdings in Exelixis were worth $3,068,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Exelixis by 2.2% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock valued at $287,794,000 after purchasing an additional 164,134 shares during the period. Geode Capital Management LLC raised its position in Exelixis by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after purchasing an additional 28,289 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Exelixis by 73.8% in the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after buying an additional 2,926,884 shares during the period. Invesco Ltd. lifted its holdings in shares of Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after buying an additional 1,596,948 shares during the period. Finally, Nuveen LLC bought a new position in shares of Exelixis during the 1st quarter worth $123,310,000. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. HC Wainwright boosted their price target on shares of Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. JMP Securities reiterated a “market outperform” rating and set a $50.00 price objective on shares of Exelixis in a research note on Tuesday, July 29th. Leerink Partners raised shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective on the stock in a report on Tuesday, October 21st. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 target price on shares of Exelixis in a report on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.45.

Exelixis Stock Up 0.5%

NASDAQ EXEL opened at $42.65 on Wednesday. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62. The company has a 50 day moving average price of $39.65 and a 200 day moving average price of $40.60. The firm has a market cap of $11.43 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. Exelixis’s revenue was up 10.8% compared to the same quarter last year. During the same period last year, the firm earned $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In related news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the transaction, the director directly owned 21,380 shares in the company, valued at $896,463.40. The trade was a 53.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stelios Papadopoulos sold 100,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares in the company, valued at $51,790,879.40. This represents a 7.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 173,005 shares of company stock valued at $7,443,678 in the last quarter. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.